Anthony A. Rayner

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Michael T. Lotze, Yvedt L. Matory, Stephen E. Ettinghausen et al. · The Journal of Immunology · 1985 · 609 citations

Clinical Immunology, Il 2, Immunotoxicology +18

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.

David C. Hohn, Robert Stagg, Michael Friedman et al. · Journal of Clinical Oncology · 1989 · 453 citations

Colorectal Cancer Metastatic, Hepatology, Gastrointestinal Oncology +14

Clinical effects and toxicity of interleukin-2 in patients with cancer

Michael T. Lotze, Yvedt L. Matory, Anthony A. Rayner et al. · Cancer · 1986 · 358 citations · Full text

Immunotoxicology, Immunology, Immunoediting +22

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Kim Margolin, Anthony A. Rayner, Michael Hawkins et al. · Journal of Clinical Oncology · 1989 · 347 citations

Management Guidelines, Solid Tumors, Immunology +18

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.

Brett T. Gemlo, Michael A. Palladino, Howard S. Jaffe et al. · PubMed · 1988 · 199 citations

Immunotoxicology, Immunology, Recombinant Interleukin 2 +18